BTIG analyst Mark Massaro maintained a Hold rating on Cerus (CERS – Research Report) yesterday. The company’s shares closed last Friday at $2.16.
Massaro covers the Healthcare sector, focusing on stocks such as Guardant Health, Personalis, and SOPHiA GENETICS. According to TipRanks, Massaro has an average return of -15.6% and a 33.00% success rate on recommended stocks.
Currently, the analyst consensus on Cerus is a Moderate Buy with an average price target of $4.00.
See the top stocks recommended by analysts >>
The company has a one-year high of $4.05 and a one-year low of $1.21. Currently, Cerus has an average volume of 1.35M.
Based on the recent corporate insider activity of 28 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CERS in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cerus (CERS) Company Description:
Cerus Corp. engages in the research, development, and manufacture of biomedical and surgical products. The firm produces blood system for platelets and plasma. It operates through Blood Safety segment. It markets products under the INTERCEPT brand. The company was founded by Laurence M. Corash and John E. Hearst on September 19, 1991 and is headquartered in Concord, CA.
Read More on CERS:
